BLPH Bellerophon Therapeutics, Inc. Stock Quote

BLPH [NASD]

Index	-	P/E	-	EPS (ttm)	-2.61	Insider Own	1.70%	Shs Outstand	9.51M	Perf Week	-0.75%
Market Cap	36.25M	Forward P/E	-	EPS next Y	-2.36	Insider Trans	-72.04%	Shs Float	9.12M	Perf Month	1.53%
Income	-24.80M	PEG	-	EPS next Q	-0.63	Inst Own	32.70%	Short Float	0.74%	Perf Quarter	-1.24%
Sales	-	P/S	-	EPS this Y	-7.70%	Inst Trans	-15.60%	Short Ratio	0.39	Perf Half Y	-31.08%
Book/sh	3.17	P/B	1.25	EPS next Y	-2.00%	ROA	-53.20%	Target Price	-	Perf Year	-62.44%
Cash/sh	3.76	P/C	1.06	EPS next 5Y	-	ROE	-67.30%	52W Range	3.66 - 11.01	Perf YTD	-40.48%
Dividend	-	P/FCF	-	EPS past 5Y	43.80%	ROI	-	52W High	-63.93%	Beta	-0.52
Dividend %	-	Quick Ratio	5.70	Sales past 5Y	-	Gross Margin	-	52W Low	8.47%	ATR	0.20
Employees	21	Current Ratio	5.70	Sales Q/Q	-	Oper. Margin	-	RSI (14)	46.79	Volatility	4.78% 5.32%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	29.50%	Profit Margin	-	Rel Volume	0.20	Prev Close	4.00
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	172.22K	Price	3.97
Recom	1.70	SMA20	-1.98%	SMA50	-4.33%	SMA200	-26.77%	Volume	34,154	Change	-0.75%

Aug-11-20

Initiated

Jefferies

Buy

$19

Jan-24-19

Initiated

Maxim Group

Buy

Apr-17-17

Initiated

Ladenburg Thalmann

Buy

$4.50

Jan-20-17

Initiated

H.C. Wainwright

Buy

Mar-22-16

Reiterated

Leerink Partners

Outperform

$11 → $9

Jul-27-15

Reiterated

FBR Capital

Outperform

$23 → $11

Mar-16-15

Initiated

FBR Capital

Outperform

$23

Sep-07-21 08:30AM	Bellerophon to Present at the H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire
Sep-03-21 08:16AM	Here's Why We're Watching Bellerophon Therapeutics' (NASDAQ:BLPH) Cash Burn Situation Simply Wall St.
Aug-05-21 08:30AM	Bellerophon Provides Clinical Program Update and Reports Second Quarter 2021 Financial Results GlobeNewswire
Jun-29-21 08:05AM	Hedge Funds Are Coming Back To Bellerophon Therapeutics, Inc. (BLPH) Insider Monkey -8.58%
Jun-18-21 11:08AM	Biogen (BIIB) Initiates Late-Stage Study on Lupus Candidate Zacks -5.54%
Jun-09-21 10:28AM	VBI Vaccines (VBIV) Up on Glioblastoma Drug Fast Track Status Zacks
10:03AM	Arena (ARNA) Starts Phase II Study on Coronary Drug Temanogrel Zacks
May-27-21 08:30AM	Bellerophon to Present at the Jefferies Virtual Healthcare Conference GlobeNewswire
May-26-21 08:30AM	Bellerophon Appoints Naseem Amin, M.D. as Chairman of its Board of Directors GlobeNewswire
May-20-21 10:14AM	Reata (RETA) Soars on Potential Omaveloxolone NDA Filing Zacks
10:02AM	Iovance (IOVA) Falls on Negative Lifileucel Regulatory Update Zacks
May-11-21 08:30AM	Bellerophon Provides Clinical Program Update and Reports First Quarter 2021 Financial Results GlobeNewswire
Mar-11-21 08:30AM	Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2020 Financial Results GlobeNewswire
Mar-02-21 08:30AM	Bellerophon to Present at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire
Jan-04-21 08:30AM	Bellerophon to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference GlobeNewswire
Dec-01-20 08:30AM	Bellerophon Therapeutics Announces First Patient Enrolled in Phase 3 REBUILD Study Evaluating INOpulse® for the Treatment of Fibrotic Interstitial Lung Disease GlobeNewswire -5.59%
Nov-28-20 08:49PM	Here is What Hedge Funds Think About Bellerophon Therapeutics, Inc. (BLPH) Insider Monkey
Nov-23-20 08:30AM	Bellerophon Therapeutics Announces Results of Interim Analysis of Phase 3 COViNOX Study of INOpulse® for the Treatment of COVID-19 GlobeNewswire -17.77%
Nov-11-20 08:30AM	Bellerophon to Present at the H.C. Wainwright 6th Annual Israel Conference GlobeNewswire
Nov-05-20 10:05AM	Bellerophon Therapeutics (BLPH) Reports Q3 Loss, Lags Revenue Estimates Zacks
08:30AM	Bellerophon Provides Clinical Program Update and Reports Third Quarter 2020 Financial Results GlobeNewswire
Oct-29-20 08:30AM	Bellerophon to Present Results from its Phase 2 iNO-PF Study of INOpulse® for the Treatment of Fibrotic Interstitial Lung Disease at Upcoming Scientific Conferences GlobeNewswire
Sep-14-20 11:49AM	Insider Buys Bellerophon Therapeutics Shares Benzinga +6.80%
08:30AM	Bellerophon to Present at Two September Investor Conferences GlobeNewswire
Aug-11-20 08:30AM	Bellerophon Appoints Cardiopulmonary Disease Expert Wassim Fares, M.D., MSCR, as Chief Medical Officer GlobeNewswire
Aug-05-20 08:30AM	Bellerophon Provides Clinical Program Update and Reports Second Quarter 2020 Financial Results GlobeNewswire
Jul-15-20 08:30AM	Bellerophon Therapeutics Announces Publication of Cohort 1 of iNO-PF Phase 2/3 Study in the CHEST Journal and Participation in Webinar to Discuss Clinical Results GlobeNewswire
Jul-13-20 08:30AM	Bellerophon Therapeutics Announces First Patient Treated in Phase 3 Clinical Study of INOpulse® Inhaled Nitric Oxide Therapy for COVID-19 GlobeNewswire
Jun-29-20 08:00AM	Bellerophon Therapeutics Added to Russell 3000® and Microcap® Indexes GlobeNewswire
Jun-04-20 06:42PM	Is Bellerophon Therapeutics, Inc. (BLPH) A Good Stock To Buy? Insider Monkey
May-29-20 03:40PM	Alan Fournier Adds 4 Stocks to Portfolio GuruFocus.com
May-22-20 09:47AM	Bellerophon Therapeutics Announces Closing of $43.7 Million Public Offering of Common Stock and Concurrent Registered Direct Offering and Full Exercise of Option to Purchase Additional Shares GlobeNewswire +7.99%
May-19-20 06:53PM	8 Biotechs Tapping Secondary Markets for $3 Billion GuruFocus.com -19.55%
07:00AM	Bellerophon Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Registered Direct Offering GlobeNewswire
May-18-20 04:03PM	Bellerophon Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
May-12-20 10:09AM	Company News for May 12, 2020 Zacks -6.02%
May-11-20 04:01PM	Bellerophon Provides Clinical Program Update and Reports First Quarter 2020 Financial Results GlobeNewswire +19.22%
08:30AM	Bellerophon Therapeutics Announces FDA Clears Initiation of Phase 3 Study for INOpulse® Inhaled Nitric Oxide Therapy to Treat COVID-19 GlobeNewswire
May-04-20 08:30AM	Bellerophon Therapeutics to Participate in COVID-19 Panel at Maxim Groups Infectious Disease Virtual Conference GlobeNewswire
Apr-17-20 12:19PM	These experimental drugs may help keep COVID-19 patients off ventilators MarketWatch
Apr-08-20 08:23PM	Covid-19: Could Bellerphon Therapeutics INOpulse Help Address Hospital Ventilator Shortage? SmarterAnalyst -8.87%
08:30AM	Bellerophon Therapeutics Submits Investigational New Drug Application to Study INOpulse® Inhaled Nitric Oxide Therapy for the Treatment of COVID-19 GlobeNewswire
Apr-06-20 10:23AM	Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2019 Financial Results GlobeNewswire
Apr-01-20 01:06PM	Bellerophon Announces Closing of $15.3 Million Registered Direct Offering of Common Stock GlobeNewswire -13.96%
Mar-31-20 08:30AM	Bellerophon Therapeutics to Host Investor Call and Webcast Today on INOpulse® for the Treatment of COVID-19 GlobeNewswire -10.89%
Mar-30-20 09:57AM	Bellerophon Announces $15.3 Million Registered Direct Offering Priced At-the-Market GlobeNewswire
08:00AM	Bellerophon Therapeutics Announces First Patient Treated with INOpulse® Inhaled Nitric Oxide Therapy for COVID-19 GlobeNewswire
Mar-29-20 03:44PM	Bellerophon Shares Jump On Covid-19 OK GuruFocus.com
Mar-23-20 09:30AM	Company News for Mar 23, 2020 Zacks -32.67%
Mar-22-20 08:19AM	3 Coronavirus Stocks with Over 60% Upside TipRanks
Mar-20-20 08:30AM	FDA Grants Bellerophon Emergency Expanded Access for INOpulse® for the Treatment of COVID-19 Virus GlobeNewswire +430.97%
Mar-10-20 08:30AM	Bellerophon Announces Agreement with the FDA on its Planned Pivotal Phase 3 Study for the Treatment of Pulmonary Hypertension Associated with Pulmonary Fibrosis GlobeNewswire -5.91%
Feb-21-20 12:11PM	The One Metric That Helps Me Find Stocks With The Greatest Potential Benzinga
Feb-19-20 10:32AM	Company News for Feb 19, 2020 Zacks -11.90%
09:21AM	Biotech Stock Roundup: INCY's Solid Q4 Results, EPZM & SGEN's Pipeline Updates Zacks
07:21AM	The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA Benzinga
Feb-18-20 08:30AM	Bellerophon Reports Positive Top-Line Data from an Ancillary Acute Hemodynamic Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Pulmonary Fibrosis GlobeNewswire +168.37%
Feb-07-20 12:00PM	Bellerophon Announces 1-for-15 Reverse Stock Split GlobeNewswire -18.75%
Dec-20-19 04:18PM	Is Bellerophon Therapeutics, Inc. (BLPH) Going to Burn These Hedge Funds? Insider Monkey
Dec-17-19 08:44AM	Bellerophon stock is up 35% on hypertension trial data MarketWatch -10.82%
07:00AM	Bellerophon Announces Positive Top-line Results from Cohort 2 of Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease GlobeNewswire
Nov-12-19 08:30AM	Bellerophon Announces Positive Initial Data from Acute Hemodynamic Dose Escalation Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease GlobeNewswire
Nov-07-19 08:30AM	Bellerophon Presents New Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at Pulmonary Fibrosis Foundation Summit 2019 GlobeNewswire
Nov-06-19 08:30AM	Bellerophon Provides Business Update and Reports Third Quarter 2019 Financial Results GlobeNewswire
Nov-01-19 11:51AM	Largest Insider Trades of the Week GuruFocus.com
Oct-28-19 07:15AM	BLPH: More Clinical Data Supports Utility of INOpulse, Near-Term Value-Inflection Opportunities Grow Zacks Small Cap Research -15.89%
Oct-23-19 08:30AM	Bellerophon Presents New Positive Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at CHEST 2019 Annual Meeting GlobeNewswire
07:54AM	The Daily Biotech Pulse: Eli Lily Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data Benzinga
Oct-20-19 08:08AM	The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict Benzinga
Oct-14-19 08:30AM	Bellerophon to Present New Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at CHEST 2019 Annual Meeting GlobeNewswire
Sep-16-19 08:30AM	Bellerophon Receives Orphan Drug Designation for Nitric Oxide in the Treatment of Idiopathic Pulmonary Fibrosis GlobeNewswire
Sep-04-19 08:30AM	Bellerophon to Present at the H.C. Wainwright 21st Annual Global Investment Conference GlobeNewswire
Aug-08-19 12:57PM	Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Insiders Increased Their Holdings Simply Wall St.
08:30AM	Bellerophon Provides Business Update and Reports Second Quarter 2019 Financial Results GlobeNewswire
Aug-06-19 08:15PM	BLPH: Zacks SCR Initiates Coverage of Bellerophon Therapeutics Zacks Small Cap Research
Aug-01-19 08:30AM	Bellerophon Completes Enrollment in Cohort 2 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease GlobeNewswire
Jun-13-19 08:00AM	Bellerophon to Present at the JMP Securities Life Sciences Conference GlobeNewswire
May-22-19 08:30AM	Bellerophon to Host Key Opinion Leader Meeting Focused on Pulmonary Hypertension Associated with Interstitial Lung Disease GlobeNewswire
May-21-19 08:30AM	Bellerophon Presents Additional Positive Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at American Thoracic Society 115th International Conference GlobeNewswire
May-18-19 09:50AM	The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs Benzinga
May-13-19 08:30AM	Bellerophon to Present Additional Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at American Thoracic Society 115th International Conference GlobeNewswire
May-09-19 08:45AM	Bellerophon Therapeutics: 1Q Earnings Snapshot Associated Press
08:30AM	Bellerophon Provides Business Update and Reports First Quarter 2019 Financial Results GlobeNewswire
May-03-19 12:10PM	What Kind Of Shareholders Own Bellerophon Therapeutics, Inc. (NASDAQ:BLPH)? Simply Wall St.
Apr-08-19 08:30AM	Bellerophon Announces Agreement with FDA on Regulatory Approval Pathway for INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease GlobeNewswire +7.53%
Mar-18-19 02:08PM	Did Changing Sentiment Drive Bellerophon Therapeuticss (NASDAQ:BLPH) Share Price Down A Painful 76%? Simply Wall St.
Mar-14-19 09:09AM	Bellerophon Therapeutics: 4Q Earnings Snapshot Associated Press
08:30AM	Bellerophon Provides Business Update and Reports Fourth Quarter and Full-Year 2018 Financial Results GlobeNewswire
Jan-28-19 08:30AM	Bellerophon to Present Clinical Data Supporting Actigraphy as a Clinically Meaningful Endpoint to Detect Improvements in Pulmonary Fibrosis Patients GlobeNewswire
Jan-25-19 04:05PM	Bellerophon Announces Closing of $7 Million Public Offering of Common Stock GlobeNewswire
Jan-23-19 06:00AM	Bellerophon Announces Pricing of $7 Million Public Offering of Common Stock GlobeNewswire -23.91%
Jan-22-19 04:44PM	Bellerophon Therapeutics, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire -7.57%
Jan-07-19 08:30AM	Bellerophon Announces Top-line Results from Cohort 1 of the INOpulse® Phase 2b Clinical Trial for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease GlobeNewswire +26.74%
Nov-21-18 08:55AM	Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-16-18 01:32AM	DBV Technologies Appoints Daniel Tassé as Chief Executive Officer GlobeNewswire
Nov-07-18 09:36AM	Bellerophon Therapeutics: 3Q Earnings Snapshot Associated Press
08:30AM	Bellerophon Provides Business Update and Reports Third Quarter 2018 Financial Results GlobeNewswire
Oct-09-18 08:30AM	Bellerophon Provides Update on INOpulse® Phase 2b Clinical Program for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease GlobeNewswire
Sep-10-18 11:40AM	3 Biotech & Marijuana Stocks to Pay Attention to this Quarter ACCESSWIRE
Aug-29-18 08:00AM	Bellerophon Therapeutics to Present at Rodman & Renshaw 20th Annual Global Investment Conference GlobeNewswire

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that is in Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with pulmonary edema from high altitude sickness, and COVID-19 patients. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
New Mountain Investments II, L	10% Owner	Mar 18	Sale	5.48	400,000	2,192,000	609,231	Mar 22 09:36 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience